PDA drag panel
BUSINESS ANALYSIS DECADAL
: IMCL is a biopharmaceutical company engaged in the research and development of novel cancer treatments. The Company focus on three promising strategies for treating cancer; growth factor inhibitors, therapeutic cancer vaccines and angiogenesis inhibitors. For the 3 months ended 3/00, revenues fell 67% to $206K. Net loss applic. to Com. rose 42% to $12.8M. Results reflect lower research & support payments, and clinical trial costs.